

## **CURRENT REPORT 1/2022**

**January 19, 2022**

### **Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center**

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company"), in the current report No 31/2021 of 24 September 2021 informed about filing a lawsuit against Mota-Engil Central Europe S.A. with its registered office in Kraków ("the Contractor"), claiming payment of PLN 13.756.717,07 PLN for the contractual penalties due under the general contractor agreement for the project entitled: "Construction of the Research and Development Center for Innovative Drugs Selvita S.A." ("Contract"), of which the Company informed in the current report no. 27/2018 dated August 13, 2018.

The Management Board of the Company informs that on January 19, 2022 the Company has been served with a lawsuit for payment filed to the Regional Court in Kraków by the Contractor in connection with the performance of the Contract. In the lawsuit the Contractor is claiming damages for the costs incurred in connection with prolonged performance of the Contract, the unpaid portion of the lump-sum fee as well as supplementary remuneration for additional, replacement and omitted works (PLN 5.391.425,63) as well as damages resulting from the Company's unauthorized - in the Contractor's opinion - application of the performance bond and removal of the defects and faults (PLN 2.063.507,56). With the statutory interests, the Contractor demands from the Company a total amount of PLN 7.671.285.

The Company disputes the validity of the claims indicated in the Contractor's statement of claim both in principle and in amount. The Company will take appropriate legal steps in order to protect its interests in connection with the claims made by the Contractor.

**Legal basis:** Art. 17.1 of MAR

#### **Representatives of the Company:**

- Paweł Przewięźlikowski – President of the Management Board
- Tomasz Nocuń – Proxy